US 12,285,429 B2
CDK inhibitors
Zhilong Hu, Shanghai (CN); Hu He, Shanghai (CN); Fei Zhang, Shanghai (CN); Wenge Zhong, Thousand Oaks, CA (US); and Xiaotian Zhu, Newton, MA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Appl. No. 17/922,804
Filed by Genentech, Inc., South San Francisco, CA (US)
PCT Filed May 4, 2021, PCT No. PCT/US2021/030728
§ 371(c)(1), (2) Date Nov. 2, 2022,
PCT Pub. No. WO2021/226140, PCT Pub. Date Nov. 11, 2021.
Claims priority of application No. PCT/CN2020/088585 (WO), filed on May 5, 2020.
Prior Publication US 2023/0174512 A1, Jun. 8, 2023
Int. Cl. C07D 401/14 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 405/14 (2006.01); C07D 487/04 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 487/04 (2013.01)] 12 Claims
 
1. A compound represented by the following structural formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.